Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 8/20 | 0.55 |
| ▸ | AURKA | O14965 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134742 | 0.89 | AURKB (0.56) | AURKBAURKAMAPTTP53SMN1; SMN2 | |
| SCHEMBL17135168 | 0.86 | AURKB (0.55) | AURKBAURKAMAPTTP53SMN1; SMN2 | |
| SCHEMBL17135080 | 0.86 | AURKB (0.62) | AURKBAURKAMAPTTP53SMN1; SMN2 | |
| SCHEMBL17134561 | 0.84 | EGFR (0.49) | AURKBAURKAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL15058850 | 0.83 | AURKB (0.48) | AURKBAURKAMAPTTP53SMN1; SMN2 | |
| SCHEMBL17031568 | 0.81 | AURKB (0.57) | AURKBAURKAMAPTTP53SMN1; SMN2 | |
| SCHEMBL2386230 | 0.80 | SYK (0.59) | AURKBMAPTTP53SMN1; SMN2 | |
| SCHEMBL17134974 | 0.79 | EGFR (0.54) | MAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL15059195 | 0.78 | AURKB (0.50) | AURKBAURKAMAPTTP53SMN1; SMN2 | |
| SCHEMBL5329104 | 0.77 | CREBBP (0.82) | AURKBAURKAMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ARG1, H1-0, TYR | AURKB 4438/4885AURKA 3400/4885MAPT 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.